If you’ve had a BioZorb Marker implanted during breast cancer treatment, you might be facing unexpected pain, infections, or worse. As of March 23, 2025, the titanium breast marker lawsuit landscape is heating up after Hologic’s October 2024 recall of all unused BioZorb devices—labeled a Class 1 recall by the FDA, its most severe category. Hundreds of patients are suing, claiming these titanium-based markers caused life-altering complications. Curious about your rights and potential payouts? Here’s the latest on this unfolding legal battle.
What Sparked the Titanium Breast Marker Lawsuit Surge?
The BioZorb Marker, a titanium-and-plastic implant meant to guide radiation post-lumpectomy, promised precision but delivered problems. Marketed by Hologic since 2012, it’s supposed to dissolve (except for its titanium clips) within a year. Yet, patients report it didn’t—triggering lawsuits nationwide. By March 2025, over 150 cases are pending in Massachusetts federal court, centralized under Judge Allison Burroughs.
Key issues:
- Recall Fallout: Hologic’s October 2024 recall followed 399 complaints, including 188 adverse events like migration and erosion, per FDA data.
- FDA Action: A December 2024 Class 1 recall cemented the risks, citing “serious injury or death” potential—though no deaths are reported yet (71 injuries noted).
- Patient Harm: Complaints highlight pain, infections, scarring, and surgical removals due to device failure.
Victims allege Hologic knew of defects but hid them, fueling the titanium breast marker lawsuit wave. Could you be eligible? Let’s explore.
Common Complaints Driving Titanium Breast Marker Lawsuits
Patients expected BioZorb to aid recovery, not hinder it. Instead, they’ve faced:
- Device Migration: The marker shifts from its implant site, causing pain or lumps.
- Erosion Issues: Titanium components poking through the skin, leading to disfigurement.
- Infections & Fluid Buildup: Persistent seromas or abscesses requiring drainage or surgery.
- Non-Dissolving Plastic: The “bioabsorbable” part lingering years past its promise, sparking chronic discomfort.
Take Jane Doe (anonymized), a 2021 lumpectomy patient from Ohio. Her BioZorb didn’t dissolve by 2023, leading to a hardened mass, surgery, and a $40,000 medical bill. Her story mirrors hundreds now suing Hologic for negligence and defective design.
Titanium Breast Marker Lawsuit Payouts: What’s at Stake?
No global settlement exists yet, but early trends suggest compensation could be significant. Based on similar medical device cases (e.g., hernia mesh lawsuits averaging $50K–$500K), here’s a 2025 estimate for titanium breast marker lawsuit payouts:
- Minor Complications: $25,000–$75,000 (e.g., treatable infections).
- Moderate Harm: $75,000–$250,000 (e.g., surgery for removal).
- Severe Cases: $250,000–$1M+ (e.g., permanent scarring, emotional distress).
Bellwether trials, starting September 8, 2025, will refine these figures. If Hologic’s liability sticks, punitive damages could push top awards higher—think $1.5M+ for egregious cases. Curious about your claim’s worth? A free consultation can clarify.
Can You Still File a Titanium Breast Marker Lawsuit in 2025?
Yes, but time’s ticking. You might qualify if:
- Had a BioZorb implanted (2012–2024).
- Suffered complications like pain, migration, or infection post-implant.
- Act within your state’s statute of limitations (typically 2-4 years from injury discovery—e.g., June 2025 for a 2023 issue).
The recall doesn’t mandate the removal of implanted devices unless symptoms arise, per the FDA. Still, over 90,000 units sold since 2015 mean thousands could be affected. Contact us at [insert number] for a no-cost case review—don’t miss your window.
How to Join the Titanium Breast Marker Lawsuit
Filing is straightforward with the right help:
- Document Everything: Gather medical records, implant dates, and complication proof.
- Consult a Lawyer: Our team offers free evaluations—no upfront fees, just a contingency cut if you win.
- File Before Deadlines: Lawsuits are individual but coordinated in Massachusetts; act fast to join the pack.
Discovery is ongoing, with core depositions wrapping by December 2025. Trials will gauge Hologic’s defenses—did they downplay risks knowingly? Early wins could spark a settlement by 2026.
Why the Titanium Breast Marker Lawsuit Matters
This isn’t just about money—it’s about accountability. X posts from survivors reveal outrage: “Trusted BioZorb to heal me, not scar me,” one wrote in March 2025. The litigation pressures Hologic to answer for alleged design flaws and inadequate warnings, potentially sparing future patients. Plus, with $1.6B in past Sokolove Law recoveries for device victims, justice can fund recovery.
Get Started on Your Titanium Breast Marker Lawsuit Today
If BioZorb turned your cancer fight into a new battle, you deserve answers—and compensation. Call us at [insert number] or fill out our online form for a free, no-risk consultation. The titanium breast marker lawsuit is your chance to reclaim control—don’t wait as deadlines loom in 2025.
Lawsuits claim BioZorb’s titanium markers caused migration and infections—Hologic recalled them in 2024.
Payouts may range from $25,000–$1M+, depending on injury severity, per 2025 estimates.
Yes, if you had BioZorb and complications—file before state deadlines hit!
